VWA
VERV

VSM Wealth Advisory’s Verve Therapeutics VERV Stock Holding History

VSM Wealth Advisory’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$11.2K – 507
2025
Q2 		$11.2K Hold
1,000
– – ﹤0.01% 368
2025
Q1 		$4.57K Hold
1,000
– – ﹤0.01% 413
2024
Q4 		$5.64K Buy
+1,000
New +$5.64K ﹤0.01% 384

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

VSM Wealth Advisory's VERV Position: Q3 2025 in Review

VSM Wealth Advisory sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,000 shares — an estimated $11.2K sold.

VSM Wealth Advisory first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $11.2K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • VSM Wealth Advisory reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • VSM Wealth Advisory sold 1,000 Verve Therapeutics shares in Q3 2025, an estimated $11.2K.
  • VSM Wealth Advisory first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • VSM Wealth Advisory's Verve Therapeutics position peaked at $11.2K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on VSM Wealth Advisory's 13F filing for Q3 2025, filed 13 Nov 2025.